Monday , November 20 2017
Home / Letter From The Editor / Dec. 19, 2016

Dec. 19, 2016

dave

When we began 2016, we were just starting to see the value of the SGLT-2 Inhibitors gain momentum. In fact, our first feature of the year looked at mixing an SGLT-2 Inhibitor with a DPP-4i and Metformin to maximize glucose control, and over the year we reviewed over 40 articles and studies on the SGLT-2 Inhibitors.

Our publisher, Steve Freed, worked with our entire staff to isolate the best of SGLT-2 Inhibitors in 2016. Take a look at these features below and see if you think you can increase your knowledge by reading the best of the best.

Dave Joffe

Editor-in-chief